APA (7th ed.) Citation

JC, B., TJ, E., D, G., J, S., JA, W., MN, S., . . . SP, H. (2013). Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. Clinical colorectal cancer, 12(3), 218. https://doi.org/10.1016/j.clcc.2013.04.001

Chicago Style (17th ed.) Citation

JC, Bendell, Ervin TJ, Gallinson D, Singh J, Wallace JA, Saleh MN, Vallone M, Phan SC, and Hack SP. "Treatment Rationale and Study Design for a Randomized, Double-blind, Placebo-controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination with Bevacizumab Plus MFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Cancer." Clinical Colorectal Cancer 12, no. 3 (2013): 218. https://doi.org/10.1016/j.clcc.2013.04.001.

MLA (9th ed.) Citation

JC, Bendell, et al. "Treatment Rationale and Study Design for a Randomized, Double-blind, Placebo-controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination with Bevacizumab Plus MFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Cancer." Clinical Colorectal Cancer, vol. 12, no. 3, 2013, p. 218, https://doi.org/10.1016/j.clcc.2013.04.001.